NYSE:SNY - Sanofi Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$38.61 -0.32 (-0.82 %)
(As of 05/23/2018 04:00 PM ET)
Previous Close$38.61
Today's Range$38.24 - $38.8250
52-Week Range$37.43 - $50.65
Volume1.50 million shs
Average Volume1.65 million shs
Market Capitalization$97.29 billion
P/E Ratio12.34
Dividend Yield4.80%
Beta0.84

About Sanofi (NYSE:SNY)

Sanofi logoSanofi provides therapeutic solutions. It offers Cerezyme and Cerdelga for Gaucher disease, Myozyme and Lumizyme for Pompe disease, Fabrazyme for Fabry disease, and Aldurazyme for mucopolysaccharidosis Type 1; and Aubagio, an oral immunomodulator and Lemtrada, a monoclonal antibody to treat multiple sclerosis. The company also provides Jevtana, a taxane derivative for prostate cancer; Taxotere, a taxoid for various cancers; Eloxatin, a platinum agent for colorectal cancer; Thymoglobulin, an immunosuppressive and immunomodulating agent; Mozobil, a hematopoietic stem cell mobilizer for hematologic malignancies; and Zaltrap, a protein for metastatic colorectal cancer. In addition, it offers Dupixent for atopic dermatitis; Kevzara for rheumatoid arthritis; Lantus, Toujeo, Apidra, and Insuman insulins; Amaryl, an oral sulfonylurea; Lyxumia/Adlyxin, a GLP-1 receptor agonist; Soliqua 100/33/Suliqua, an insulin glargine and lixisenatide combination to treat diabetes; Admelog/Insulin lispro insulin; and Praluent, a cholesterol-lowering drug and Multaq, an anti-arrhythmic drug for atrial fibrillation. Further, the company provides Plavix, an anti-platelet agent for atherothrombotic conditions; Lovenox, a heparin for the prophylaxis and treatment of venous thromboembolism and acute coronary syndrome; Aprovel and CoAprovel anti-hypertensives; Renagel and Renvela oral phosphate binders for patients undergoing dialysis; Synvisc and Synvisc-One viscosupplements for patients with osteoarthritis; Stilnox for treatment of insomnia; and Allegra, an anti-histamine for the treatment of seasonal allergic rhinitis and uncomplicated hives. Additionally, it offers consumer health care products and generic medicines; and pediatric, influenza, adult and adolescent booster, meningitis, and travel and endemic vaccines. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was founded in 1973 and is headquartered in Paris, France.

Receive SNY News and Ratings via Email

Sign-up to receive the latest news and ratings for SNY and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNYSE:SNY
CUSIPN/A
Phone33-1-53-77-44-00

Debt

Debt-to-Equity Ratio0.25
Current Ratio1.70
Quick Ratio1.26

Price-To-Earnings

Trailing P/E Ratio12.34
Forward P/E Ratio12.10
P/E Growth1.85

Sales & Book Value

Annual Sales$39.60 billion
Price / Sales2.45
Cash Flow$4.7491 per share
Price / Cash8.13
Book Value$26.11 per share
Price / Book1.48

Profitability

EPS (Most Recent Fiscal Year)$3.13
Net Income$4.28 billion
Net Margins10.93%
Return on Equity24.45%
Return on Assets14.07%

Miscellaneous

Employees106,859
Outstanding Shares2,508,090,000

Sanofi (NYSE:SNY) Frequently Asked Questions

What is Sanofi's stock symbol?

Sanofi trades on the New York Stock Exchange (NYSE) under the ticker symbol "SNY."

How often does Sanofi pay dividends? What is the dividend yield for Sanofi?

Sanofi announced an annual dividend on Tuesday, February 13th. Investors of record on Thursday, May 10th will be paid a dividend of $1.8609 per share on Monday, June 4th. This represents a dividend yield of 4.72%. The ex-dividend date of this dividend is Wednesday, May 9th. This is a boost from Sanofi's previous annual dividend of $1.58. View Sanofi's Dividend History.

How were Sanofi's earnings last quarter?

Sanofi (NYSE:SNY) announced its quarterly earnings results on Friday, April, 27th. The company reported $0.79 earnings per share for the quarter, topping the Zacks' consensus estimate of $0.74 by $0.05. The company earned $7.90 billion during the quarter, compared to analyst estimates of $7.88 billion. Sanofi had a net margin of 10.93% and a return on equity of 24.45%. The company's revenue for the quarter was down 8.7% on a year-over-year basis. During the same quarter in the prior year, the business posted $1.42 EPS. View Sanofi's Earnings History.

When is Sanofi's next earnings date?

Sanofi is scheduled to release their next quarterly earnings announcement on Monday, July, 30th 2018. View Earnings Estimates for Sanofi.

What guidance has Sanofi issued on next quarter's earnings?

Sanofi updated its second quarter earnings guidance on Friday, April, 27th. The company provided earnings per share (EPS) guidance of EUR 1.28 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $1.15.

What price target have analysts set for SNY?

11 Wall Street analysts have issued 1-year price targets for Sanofi's shares. Their forecasts range from $45.00 to $55.00. On average, they expect Sanofi's stock price to reach $49.3333 in the next year. View Analyst Ratings for Sanofi.

What are Wall Street analysts saying about Sanofi stock?

Here are some recent quotes from research analysts about Sanofi stock:
  • 1. According to Zacks Investment Research, "Sanofi’s Diabetes franchise is under significant pressure with key product, Lantus facing increasing competitive pressure at the payor level and the presence of biosimilar competition in several European markets and Japan. The declining trends in the diabetes franchise are expected to continue in 2018. Meanwhile, the performance of the Consumer Healthcare franchise was soft in 2017. Moreover, Sanofi’s shares have underperformed the industry this year so far. Other headwinds include generic competition and slower-than-expected uptake of new products like Praluent. However, Sanofi's focus on streamlining its business and pursuing business development deals is encouraging. Further, the acquisitions of Ablynx and Bioverativ are expected to strengthen Sanofi’s position in the rare blood disorders market. Sanofi has a mixed record of earnings surprises in recent quarters. Estimates movement has been mixed ahead of Q1 results." (4/17/2018)
  • 2. Argus analysts commented, "The company also has a strong new drug pipeline that includes Toujeo, a next-generation insulin product, and dipilumab, for atopic dermatitis and other inflammatory conditions," the analyst said.See also: Where Does Zika Virus Vaccine Research Stand Now? FY18 ExpectationsArgus expects the company's 2017 revenues from continuing operations to benefit from the recent acquisition of Boehringer Ingelheim's consumer health business and higher sales of multiple sclerosis products. At the same time, the firm expects reduced diabetes drug sales.The firm also sees margin pressure due to pricing pressures for diabetes products in the U.S. and costs related to the launch of Dupixent and Kevzara, partly offset by a sales force reorganization and other cost-savings initiatives."In 2018, we expect continued solid demand for multiple sclerosis drugs and increased sales in emerging markets to outweigh weaker sales of diabetes drugs, and look for the company's cost-savings program to benefit margins," (9/1/2017)

Who are some of Sanofi's key competitors?

Who are Sanofi's key executives?

Sanofi's management team includes the folowing people:
  • Mr. Olivier Brandicourt, CEO & Director (Age 62)
  • Mr. Jérôme Contamine, CFO & Exec. VP (Age 61)
  • Mr. Laurent Gilhodes, Principal Accounting Officer and VP of Corp. Accounting
  • Mr. Bruno Ménard, Chief Information officer
  • Mr. George Grofik, Head of Investor Relations

Has Sanofi been receiving favorable news coverage?

Media coverage about SNY stock has been trending positive this week, Accern Sentiment Analysis reports. Accern ranks the sentiment of news coverage by reviewing more than 20 million blog and news sources in real time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Sanofi earned a news sentiment score of 0.27 on Accern's scale. They also gave media stories about the company an impact score of 46.03 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock's share price in the near term.

Who are Sanofi's major shareholders?

Sanofi's stock is owned by many different of retail and institutional investors. Top institutional investors include Barrow Hanley Mewhinney & Strauss LLC (0.86%), Franklin Resources Inc. (0.83%), Fisher Asset Management LLC (0.60%), BlackRock Inc. (0.13%), Wells Fargo & Company MN (0.11%) and Federated Investors Inc. PA (0.09%). View Institutional Ownership Trends for Sanofi.

Which major investors are selling Sanofi stock?

SNY stock was sold by a variety of institutional investors in the last quarter, including Barrow Hanley Mewhinney & Strauss LLC, Senzar Asset Management LLC, Federated Investors Inc. PA, Sei Investments Co., Envestnet Asset Management Inc., Russell Investments Group Ltd., Eversept Partners LLC and Jane Street Group LLC. View Insider Buying and Selling for Sanofi.

Which major investors are buying Sanofi stock?

SNY stock was purchased by a variety of institutional investors in the last quarter, including Fisher Asset Management LLC, Sio Capital Management LLC, Willis Investment Counsel, Sensato Investors LLC, BlackRock Inc., Summit Trail Advisors LLC, CIBC World Markets Inc. and Point72 Asset Management L.P.. View Insider Buying and Selling for Sanofi.

How do I buy shares of Sanofi?

Shares of SNY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Sanofi's stock price today?

One share of SNY stock can currently be purchased for approximately $38.61.

How big of a company is Sanofi?

Sanofi has a market capitalization of $97.29 billion and generates $39.60 billion in revenue each year. The company earns $4.28 billion in net income (profit) each year or $3.13 on an earnings per share basis. Sanofi employs 106,859 workers across the globe.

How can I contact Sanofi?

Sanofi's mailing address is 54 RUE LA BOETIE, PARIS I0, 75008. The company can be reached via phone at 33-1-53-77-44-00 or via email at [email protected]


MarketBeat Community Rating for Sanofi (SNY)

Community Ranking:  2.1 out of 5 (star star)
Outperform Votes:  294 (Vote Outperform)
Underperform Votes:  390 (Vote Underperform)
Total Votes:  684
MarketBeat's community ratings are surveys of what our community members think about Sanofi and other stocks. Vote "Outperform" if you believe SNY will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SNY will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Sanofi (NYSE:SNY) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
11 Wall Street analysts have issued ratings and price targets for Sanofi in the last 12 months. Their average twelve-month price target is $49.3333, suggesting that the stock has a possible upside of 27.77%. The high price target for SNY is $55.00 and the low price target for SNY is $45.00. There are currently 2 sell ratings, 6 hold ratings and 3 buy ratings for the stock, resulting in a consensus rating of "Hold."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: HoldHoldHoldHold
Consensus Rating Score: 2.092.081.912.40
Ratings Breakdown: 2 Sell Rating(s)
6 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
2 Sell Rating(s)
7 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
2 Sell Rating(s)
8 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
6 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $49.3333$49.3333$49.3333$53.50
Price Target Upside: 27.77% upside21.63% upside22.14% upside19.82% upside

Sanofi (NYSE:SNY) Consensus Price Target History

Price Target History for Sanofi (NYSE:SNY)

Sanofi (NYSE:SNY) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
4/16/2018Deutsche BankReiterated RatingBuyLowView Rating Details
3/23/2018Liberum CapitalUpgradeHold ➝ BuyLowView Rating Details
2/8/2018Sanford C. BernsteinReiterated RatingMarket Perform$50.00 ➝ $45.00LowView Rating Details
1/23/2018BarclaysDowngradeEqual Weight ➝ UnderweightLowView Rating Details
1/15/2018UBSReiterated RatingNeutralLowView Rating Details
1/11/2018JPMorgan Chase & Co.Reiterated RatingNeutralLowView Rating Details
1/2/2018Nord/LBReiterated RatingNeutralLowView Rating Details
12/18/2017CowenSet Price TargetHold$48.00LowView Rating Details
12/6/2017Bank of AmericaDowngradeBuy ➝ NeutralLowView Rating Details
12/1/2017Morgan StanleyDowngradeOverweight ➝ UnderweightLowView Rating Details
9/1/2017ArgusReiterated RatingBuy$55.00MediumView Rating Details
5/11/2017Berenberg BankDowngradeBuy ➝ HoldLowView Rating Details
2/9/2017NatixisUpgradeNeutral ➝ BuyN/AView Rating Details
1/10/2017Leerink SwannReiterated RatingOutperformN/AView Rating Details
1/8/2017Goldman Sachs GroupReiterated RatingHoldN/AView Rating Details
9/23/2016Piper Jaffray CompaniesInitiated CoverageNeutralN/AView Rating Details
9/14/2016Jefferies GroupReiterated RatingHoldN/AView Rating Details
9/13/2016BNP ParibasUpgradeUnderperform ➝ NeutralN/AView Rating Details
6/28/2016CitigroupReiterated RatingNeutralN/AView Rating Details
(Data available from 5/23/2016 forward)

Earnings

Sanofi (NYSE:SNY) Earnings History and Estimates Chart

Earnings by Quarter for Sanofi (NYSE:SNY)

Sanofi (NYSE:SNY) Earnings Estimates

Current Year EPS Consensus Estimate: $3.19 EPS
Next Year EPS Consensus Estimate: $3.56 EPS

Sanofi (NYSE SNY) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
7/30/2018        
4/27/20183/31/2018$0.74$0.79$7.8757 billion$7.8980 billionViewN/AView Earnings Details
2/7/2018Q4 2017$0.69$0.62$8.6474 billion$8.6910 billionViewListenView Earnings Details
11/2/2017Q3 2017$1.00$1.00$10.9322 billion$10.6349 billionViewN/AView Earnings Details
7/31/20176/30/2017$0.74$0.74$8.7078 billion$8.6630 billionViewN/AView Earnings Details
4/28/20173/31/2017$0.73$0.76$8.4033 billion$8.6480 billionViewN/AView Earnings Details
2/8/2017Q416$0.66$0.67$9.87 billion$8.8760 billionViewN/AView Earnings Details
10/28/2016Q3 2016$0.86$1.00$10.9850 billion$10.0711 billionViewN/AView Earnings Details
7/29/2016Q2 2016$0.74$0.74$10.2007 billion$9.1966 billionViewN/AView Earnings Details
4/29/2016Q1 2016$0.72$0.74$9.7608 billion$9.4234 billionViewN/AView Earnings Details
2/9/2016Q4 2015$0.69$0.72$10.5674 billion$10.0666 billionViewN/AView Earnings Details
10/29/2015Q315$0.8750$0.89$10.9740 billion$10.6690 billionViewN/AView Earnings Details
7/30/2015Q2 2015$0.72$0.78$10.1178 billion$10.3749 billionViewN/AView Earnings Details
4/30/2015Q115$0.61$0.73$9.2130 billion$9.7803 billionViewN/AView Earnings Details
2/5/2015Q4$0.89$0.79$11.3425 billion$10.3867 billionViewN/AView Earnings Details
10/28/2014Q3 2014$0.94$0.94$12.0653 billion$11.1463 billionViewN/AView Earnings Details
7/31/2014Q2$0.79$0.72$11.1890 billion$10.8189 billionViewN/AView Earnings Details
4/29/2014Q114$0.84$0.81$11.1915 billion$10.8805 billionViewN/AView Earnings Details
2/6/2014Q4$0.88$0.93$11.3433 billion$11.4381 billionViewN/AView Earnings Details
10/30/2013$1.01$0.93$11.8267 billion$11.5891 billionViewN/AView Earnings Details
8/1/2013Q2 2013$0.89$0.73$11.1582 billion$10.5990 billionViewN/AView Earnings Details
5/2/2013Q1 2013$0.89$0.80$10.9992 billion$10.6034 billionViewN/AView Earnings Details
2/7/2013Q4 2012$0.77$0.78ViewN/AView Earnings Details
10/25/2012Q3 2012$0.99$1.10ViewN/AView Earnings Details
7/26/2012Q2 2012$0.84$0.90ViewN/AView Earnings Details
4/27/2012Q1 2012$1.13$1.22ViewN/AView Earnings Details
2/8/2012Q4 2011$1.00$1.02ViewN/AView Earnings Details
11/3/2011Q3 2011$1.21$1.24ViewN/AView Earnings Details
7/28/2011Q2 2011$1.18$0.56ViewN/AView Earnings Details
4/28/2011Q1 2011$1.16$1.22ViewN/AView Earnings Details
2/9/2011Q4 2010$0.95$0.96ViewN/AView Earnings Details
10/28/2010Q3 2010$1.17$1.30ViewN/AView Earnings Details
7/29/2010Q2 2010$1.08$0.85ViewN/AView Earnings Details
4/29/2010Q1 2010$1.18$1.23ViewN/AView Earnings Details
2/10/2010Q4 2009$0.92$0.94ViewN/AView Earnings Details
10/30/2009Q3 2009$1.21$1.26ViewN/AView Earnings Details
7/29/2009Q2 2009$1.04$1.24ViewN/AView Earnings Details
4/29/2009Q1 2009$0.86$1.08ViewN/AView Earnings Details
2/11/2009Q4 2008$0.82$0.82ViewN/AView Earnings Details
10/31/2008Q3 2008$0.97$1.07ViewN/AView Earnings Details
7/31/2008Q2 2008$1.07$1.04ViewN/AView Earnings Details
4/30/2008Q1 2008$2.48$2.14ViewN/AView Earnings Details
2/12/2008Q4 2007$0.76$0.82ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Sanofi (NYSE:SNY) Dividend Information

Sanofi pays an annual dividend of $1.86 per share, with a dividend yield of 4.82%. SNY's next annual dividend payment will be made on Monday, June 4. Sanofi pays out 59.42% of its earnings out as a dividend.
Next Dividend:6/4/2018
Annual Dividend:$1.86
Dividend Yield:4.82%
Dividend Growth:-4.90% (3 Year Average)
Payout Ratio(s):59.42% (Trailing 12 Months of Earnings)
58.31% (Based on This Year's Estimates)
52.25% (Based on Next Year's Estimates)
39.17% (Based on Cash Flow)
Dividend Payments by Quarter for Sanofi (NYSE:SNY)

Sanofi (NYSE:SNY) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
2/13/2018annual$1.86094.72%5/9/20185/10/20186/4/2018
2/17/2017annual$1.57713.65%5/11/20175/15/20176/7/2017
2/22/2016Annual$1.10105/5/20165/9/20166/1/2016
2/26/2015special$1.61813.91%5/6/20155/8/20156/2/2015
(Data available from 1/1/2013 forward)

Insider Trades

Sanofi (NYSE SNY) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 1.00%
Institutional Ownership Percentage: 8.46%
Insider Trading History for Sanofi (NYSE:SNY)
Institutional Ownership by Quarter for Sanofi (NYSE:SNY)

Sanofi (NYSE SNY) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
8/24/2017SanofiMajor ShareholderBuy105,820$482.04$51,009,472.80View SEC Filing  
8/23/2017SanofiMajor ShareholderBuy60,595$478.98$29,023,793.10View SEC Filing  
7/9/2014SanofiMajor ShareholderBuy195,000$308.27$60,112,650.00View SEC Filing  
7/8/2014SanofiMajor ShareholderBuy153,000$311.67$47,685,510.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Sanofi (NYSE SNY) News Headlines

Source:
DateHeadline
Lexicon Pharma (LXRX), Sanofi (SNY) Announce FDA to Review Zynquista as Potential Treatment for Type 1 DiabetesLexicon Pharma (LXRX), Sanofi (SNY) Announce FDA to Review Zynquista as Potential Treatment for Type 1 Diabetes
www.streetinsider.com - May 22 at 8:29 AM
Is This European Drug Stock Giant a Buy?Is This European Drug Stock Giant a Buy?
finance.yahoo.com - May 21 at 8:28 AM
$0.74 Earnings Per Share Expected for Sanofi (SNY) This Quarter$0.74 Earnings Per Share Expected for Sanofi (SNY) This Quarter
www.americanbankingnews.com - May 21 at 5:18 AM
Sanofi (SNY) Receives Consensus Rating of "Hold" from BrokeragesSanofi (SNY) Receives Consensus Rating of "Hold" from Brokerages
www.americanbankingnews.com - May 18 at 1:40 AM
BRIEF-Sanofi announes some positive Phase 3 trials for Dupixent® (dupilumab)BRIEF-Sanofi announes some positive Phase 3 trials for Dupixent® (dupilumab)
www.reuters.com - May 16 at 8:38 AM
Sanofis Dupixent meets atopic dermatitis targetsSanofi's Dupixent meets atopic dermatitis targets
www.marketwatch.com - May 16 at 8:38 AM
Wired News – Sanofi and Ablynx Announce Results of the Initial Tender Offer Period and Commencement of Squeeze-Out Tender PeriodWired News – Sanofi and Ablynx Announce Results of the Initial Tender Offer Period and Commencement of Squeeze-Out Tender Period
finance.yahoo.com - May 16 at 8:38 AM
Dupixent® (dupilumab) showed positive Phase 3 results in adolescents with inadequately controlled moderate-to-severe atopic dermatitisDupixent® (dupilumab) showed positive Phase 3 results in adolescents with inadequately controlled moderate-to-severe atopic dermatitis
finance.yahoo.com - May 16 at 8:38 AM
Positive Phase 3 Trial of DUPIXENT® (dupilumab) in Adolescents with Inadequately Controlled Moderate-to-severe Atopic DermatitisPositive Phase 3 Trial of DUPIXENT® (dupilumab) in Adolescents with Inadequately Controlled Moderate-to-severe Atopic Dermatitis
www.prnewswire.com - May 16 at 2:42 AM
Sanofi: Dupixent® (dupilumab) showed positive Phase 3 results in adolescents with inadequately controlled moderate-to-severe atopic dermatitisSanofi: Dupixent® (dupilumab) showed positive Phase 3 results in adolescents with inadequately controlled moderate-to-severe atopic dermatitis
feeds.benzinga.com - May 16 at 2:42 AM
Sanofi: Accelerating Future Breakthroughs Through Clinical Trials - Part 1 of 3Sanofi: Accelerating Future Breakthroughs Through Clinical Trials - Part 1 of 3
www.prnewswire.com - May 14 at 1:13 PM
Sanofi-Ablynx deal goes aheadSanofi-Ablynx deal goes ahead
www.marketwatch.com - May 14 at 8:46 AM
Sanofi owns over 95% of Ablynx after tender offersSanofi owns over 95% of Ablynx after tender offers
seekingalpha.com - May 14 at 7:52 AM
Sanofi (SNY) and Agile Therapeutics (AGRX) Financial SurveySanofi (SNY) and Agile Therapeutics (AGRX) Financial Survey
www.americanbankingnews.com - May 12 at 1:14 AM
Esophageal Cancer Market Report 2018: Sanofi Dominates Clinical Activity With 86 Completed Trials ...Esophageal Cancer Market Report 2018: Sanofi Dominates Clinical Activity With 86 Completed Trials ...
www.businesswire.com - May 11 at 8:48 AM
Influenza A Viral Infections Drug Development Pipeline Report 2018 - Key Companies Include Sanofi, Seqirus and ...Influenza A Viral Infections Drug Development Pipeline Report 2018 - Key Companies Include Sanofi, Seqirus and ...
www.prnewswire.com - May 11 at 8:48 AM
Form SC TO-T/A Ablynx NV Filed by: SanofiForm SC TO-T/A Ablynx NV Filed by: Sanofi
www.streetinsider.com - May 7 at 8:31 AM
With A -24.41% Earnings Drop, Is Sanofi’s (EPA:SAN) A Concern?With A -24.41% Earnings Drop, Is Sanofi’s (EPA:SAN) A Concern?
finance.yahoo.com - May 7 at 8:31 AM
Sanofi (SNY) Downgraded by ValuEngine to "Sell"Sanofi (SNY) Downgraded by ValuEngine to "Sell"
www.americanbankingnews.com - May 2 at 6:06 PM
Analysts’ Recommendations for Eli Lilly and Peers in AprilAnalysts’ Recommendations for Eli Lilly and Peers in April
finance.yahoo.com - May 2 at 8:34 AM
BRIEF-Regeneron And Sanofi To Lower Net Price Of Praluent For Express Scripts PatientsBRIEF-Regeneron And Sanofi To Lower Net Price Of Praluent For Express Scripts Patients
www.reuters.com - May 1 at 8:37 AM
Stock Traders Buy Large Volume of Call Options on Sanofi (SNY)Stock Traders Buy Large Volume of Call Options on Sanofi (SNY)
www.americanbankingnews.com - May 1 at 7:16 AM
BRIEF-Sanofi: FDA To Conduct Priority Review Of Cemiplimab As Potential Treatment For Advanced Cutaneous ...BRIEF-Sanofi: FDA To Conduct Priority Review Of Cemiplimab As Potential Treatment For Advanced Cutaneous ...
www.reuters.com - April 30 at 8:36 AM
Maybe Sanofi Needed Those Expensive Deals After AllMaybe Sanofi Needed Those Expensive Deals After All
www.bloomberg.com - April 28 at 8:46 AM
Sanofi (SNY) Posts Quarterly  Earnings Results, Beats Estimates By $0.05 EPSSanofi (SNY) Posts Quarterly Earnings Results, Beats Estimates By $0.05 EPS
www.americanbankingnews.com - April 27 at 6:34 PM
Sanofi SA Shares Slip on Falling SalesSanofi SA Shares Slip on Falling Sales
investorplace.com - April 27 at 12:27 PM
Sanofi (SNY) Releases Q2 Earnings GuidanceSanofi (SNY) Releases Q2 Earnings Guidance
www.americanbankingnews.com - April 27 at 9:50 AM
Earnings Reaction History: Sanofi-Aventis, 30.0% Follow-Through Indicator, 1.7% SensitiveEarnings Reaction History: Sanofi-Aventis, 30.0% Follow-Through Indicator, 1.7% Sensitive
www.nasdaq.com - April 27 at 8:46 AM
Sanofi Stumbles as Key Medicines Sales Spark Growth ConcernsSanofi Stumbles as Key Medicines' Sales Spark Growth Concerns
www.bloomberg.com - April 27 at 8:46 AM
Sanofi sales, income fall, buybacks announcedSanofi sales, income fall, buybacks announced
www.marketwatch.com - April 27 at 8:46 AM
Sanofi: First-quarter 2018 Business EPS up 1.4% at CERSanofi: First-quarter 2018 Business EPS up 1.4% at CER
finance.yahoo.com - April 27 at 8:46 AM
How Is Novo Nordisk Positioned before 1Q18?How Is Novo Nordisk Positioned before 1Q18?
finance.yahoo.com - April 27 at 8:46 AM
Applied BioMath, LLC Announces Collaboration with Sanofi Genzyme for Systems Pharmacology Modeling of ...Applied BioMath, LLC Announces Collaboration with Sanofi Genzyme for Systems Pharmacology Modeling of ...
www.prnewswire.com - April 25 at 8:30 AM
Tresiba Could Significantly Drive Novo Nordisk’s Revenue in 2018Tresiba Could Significantly Drive Novo Nordisk’s Revenue in 2018
finance.yahoo.com - April 25 at 8:30 AM
Novo Nordisk’s Xultophy Expected to See High Growth in 2018Novo Nordisk’s Xultophy Expected to See High Growth in 2018
finance.yahoo.com - April 25 at 8:30 AM
Boehringers operating income up 20.7 percent on Sanofi dealBoehringer's operating income up 20.7 percent on Sanofi deal
finance.yahoo.com - April 25 at 8:30 AM
Meditope Receives BioLabs Golden Ticket Award From Sanofi to Advance Bioconjugation Technology ResearchMeditope Receives BioLabs Golden Ticket Award From Sanofi to Advance Bioconjugation Technology Research
globenewswire.com - April 24 at 8:30 AM
Sanofi SA (SNY) Receives Average Recommendation of "Hold" from BrokeragesSanofi SA (SNY) Receives Average Recommendation of "Hold" from Brokerages
www.americanbankingnews.com - April 23 at 1:48 AM
More Than 25 Data Presentations from Sanofi Genzymes Multiple Sclerosis Franchise to Be Featured at AANMore Than 25 Data Presentations from Sanofi Genzyme's Multiple Sclerosis Franchise to Be Featured at AAN
www.businesswire.com - April 20 at 8:38 AM
Sanofi (SNY) to Release Earnings on FridaySanofi (SNY) to Release Earnings on Friday
www.americanbankingnews.com - April 20 at 1:20 AM
Sanofi (SNY) CFO Jerome Contamine to Step Down Later This Year, Informed Company of Plans to Retire - Bloomberg ...Sanofi (SNY) CFO Jerome Contamine to Step Down Later This Year, Informed Company of Plans to Retire - Bloomberg ...
www.streetinsider.com - April 18 at 8:30 AM
Sanofi CFO Jerome Contamine to exit later in 2018Sanofi CFO Jerome Contamine to exit later in 2018
www.marketwatch.com - April 18 at 8:30 AM
UPDATE 2-Sanofi in talks to sell generics arm to Advent for $2.4 blnUPDATE 2-Sanofi in talks to sell generics arm to Advent for $2.4 bln
www.lse.co.uk - April 17 at 5:44 PM
Sanofi (SNY) Lowered to "Sell" at Zacks Investment ResearchSanofi (SNY) Lowered to "Sell" at Zacks Investment Research
www.americanbankingnews.com - April 17 at 11:37 AM
Sanofi in talks to sell generics arm Zentiva to Advent for 1.9 billion eurosSanofi in talks to sell generics arm Zentiva to Advent for 1.9 billion euros
www.reuters.com - April 17 at 8:47 AM
Sanofi to Sell Generics for $2.4 Billion to Focus on BiotechSanofi to Sell Generics for $2.4 Billion to Focus on Biotech
www.bloomberg.com - April 17 at 8:47 AM
[$$] Advent in Exclusivity to Buy Czech Drugmaker Zentiva for €1.9 Billion[$$] Advent in Exclusivity to Buy Czech Drugmaker Zentiva for €1.9 Billion
finance.yahoo.com - April 17 at 8:47 AM
Sanofi (SNY) Downgraded by BidaskClub to SellSanofi (SNY) Downgraded by BidaskClub to Sell
www.americanbankingnews.com - April 16 at 5:24 PM
Sanofi SA (SNY) Expected to Post Earnings of $0.84 Per ShareSanofi SA (SNY) Expected to Post Earnings of $0.84 Per Share
www.americanbankingnews.com - April 16 at 5:14 PM
Advent Near Deal to Buy Sanofis (SNY) Generics Unit - BloombergAdvent Near Deal to Buy Sanofi's (SNY) Generics Unit - Bloomberg
www.streetinsider.com - April 16 at 8:29 AM

SEC Filings

Sanofi (NYSE:SNY) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Sanofi (NYSE:SNY) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Sanofi (NYSE SNY) Stock Chart for Wednesday, May, 23, 2018

Loading chart…

This page was last updated on 5/23/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.